CAREERS at QurAlis

About the Company

About the Company
QurAlis is specifically focused on discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease. ALS is a devastating disease which causes rapid death of motor neurons leading to paralysis and an inability to speak and breathe, with an average life expectancy of only 3 years and an age of onset averaging 55. Recent advances in DNA sequencing show that ALS can be caused by mutations in more than 20 different genes and is actually a combination of multiple different sub-forms of the disease. About half the genes involved in ALS are also involved in frontotemporal dementia (FTD). It is therefore unlikely that all ALS patients can be treated the same way.

The QurAlis strategy is to go for ALS one gene at a time. We do this by using a transformative system in which cells from ALS patients are used to model the disease in a dish to identify new drugs. Two of the founders of QurAlis, Harvard professors Kevin Eggan and Clifford Woolf have pioneered this technology for ALS resulting in the discovery of a new drug target for normalizing hyperexcitability in ALS, Kv7, which was successfully tested in a phase 2 clinical trial. QurAlis has developed 3 programs which will bring new therapies to ALS patients.

QurAlis provides best-in-class R&D for:
• Patient derived stem cell technology
• Motor neuron drug discovery,
• Antisense oligonucleotide therapeutics,
• Mechanistic studies,
• Model development and model validation.


Open Positions


Whether you or a loved one is battling ALS and you want to be a part of our clinical trials, or you want to invest in the fight against this debilitating disease, we want to hear from you. Fill out the form below today and we will get back to you as quickly as possible.

  • This field is for validation purposes and should be left unchanged.